Ionis Enlists Bicycle To Open Up New Antisense Targets In Bounce-Back Bid

Aiming To Cross Blood Brain Barrier

 
• By Andrew McConaghie
  
Ionis HQ
Ionis has three products on the market, but is still loss-making and needs to expand the reach of its RNA-based medicines. • Source: Ionis
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip